[go: up one dir, main page]

BRPI0908715A2 - métodos para tratamento da psoríase - Google Patents

métodos para tratamento da psoríase

Info

Publication number
BRPI0908715A2
BRPI0908715A2 BRPI0908715A BRPI0908715A BRPI0908715A2 BR PI0908715 A2 BRPI0908715 A2 BR PI0908715A2 BR PI0908715 A BRPI0908715 A BR PI0908715A BR PI0908715 A BRPI0908715 A BR PI0908715A BR PI0908715 A2 BRPI0908715 A2 BR PI0908715A2
Authority
BR
Brazil
Prior art keywords
methods
psoriasis treatment
psoriasis
treatment
Prior art date
Application number
BRPI0908715A
Other languages
English (en)
Inventor
Joaquin Mario Valdes
Susan K Paulson
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of BRPI0908715A2 publication Critical patent/BRPI0908715A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
BRPI0908715A 2008-03-18 2009-03-11 métodos para tratamento da psoríase BRPI0908715A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US6984008P 2008-03-18 2008-03-18
US9527508P 2008-09-08 2008-09-08
US20790409P 2009-02-18 2009-02-18
PCT/US2009/036765 WO2009117289A2 (en) 2008-03-18 2009-03-11 Methods for treating psoriasis

Publications (1)

Publication Number Publication Date
BRPI0908715A2 true BRPI0908715A2 (pt) 2016-05-03

Family

ID=41091468

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0908715A BRPI0908715A2 (pt) 2008-03-18 2009-03-11 métodos para tratamento da psoríase

Country Status (16)

Country Link
US (2) US8178092B2 (pt)
EP (2) EP2810954A3 (pt)
JP (1) JP2011515404A (pt)
KR (1) KR20100126515A (pt)
CN (1) CN102037011A (pt)
AU (1) AU2009225797A1 (pt)
BR (1) BRPI0908715A2 (pt)
CA (1) CA2717569A1 (pt)
HK (1) HK1203516A1 (pt)
IL (1) IL208069A0 (pt)
MX (1) MX2010010265A (pt)
NZ (2) NZ587765A (pt)
RU (2) RU2497545C2 (pt)
SG (1) SG188909A1 (pt)
TW (2) TWI461210B (pt)
WO (1) WO2009117289A2 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
SG177982A1 (en) * 2007-01-16 2012-02-28 Abbott Lab Methods for treating psoriasis
AU2008233173B2 (en) * 2007-03-29 2013-09-19 Abbvie Inc. Crystalline anti-human IL-12 antibodies
BRPI0908715A2 (pt) 2008-03-18 2016-05-03 Abbott Lab métodos para tratamento da psoríase
US20090269398A1 (en) * 2008-04-26 2009-10-29 Vilambi Nrk Reddy Compositions for the encapsulation of natural product extracts in oil medium in hard gelatin capsules and a method of encapsulation
BRPI0921320A2 (pt) * 2008-11-28 2018-05-22 Abbott Laboratories composições de anticorpo estáveis e métodos para estabilizar os mesmos
TW201127400A (en) * 2009-09-14 2011-08-16 Abbott Lab Methods for treating psoriasis
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
US20110287018A1 (en) * 2010-05-19 2011-11-24 Philip Bosch Methods of Treating Interstitial Cystitis
BR112013008528A2 (pt) * 2010-10-06 2019-09-24 Abbvie Inc métodos para tratar psoríase
US10775379B2 (en) * 2013-03-12 2020-09-15 Abbott Laboratories Reagents, systems and methods for analyzing white blood cells
AP2015008801A0 (en) * 2013-03-15 2015-10-31 Amgen Inc Methods for treating crohn's disease using an anti-il23 antibody
AU2014238148A1 (en) * 2013-03-15 2015-10-08 Amgen Inc. Methods for treating psoriasis using an anti-IL-23 antibody
US10858422B2 (en) 2016-05-31 2020-12-08 Abcentra, Llc Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody
JP7357646B2 (ja) 2018-05-29 2023-10-06 アブセントラ,エルエルシー 乾癬の治療のための組成物及び方法
WO2025083549A1 (en) 2023-10-16 2025-04-24 Sun Pharma Advanced Research Company Limited Methods and combinations of inhibitors of il-23 pathway and modulators of s1p signaling pathway for the treatment of autoimmune disorders

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6914A (en) 1849-11-27 Propeller
US128A (en) 1837-02-16 Holdback for sleds
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5811523A (en) * 1988-11-10 1998-09-22 Trinchieri; Giorgio Antibodies to natural killer stimulatory factor
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ATE168416T1 (de) 1989-10-05 1998-08-15 Optein Inc Zellfreie synthese und isolierung von genen und polypeptiden
US5780597A (en) * 1989-12-22 1998-07-14 Hoffmann-La Roche Inc. Monoclonal antibodies to cytotoxic lymphocyte maturation factor
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6713610B1 (en) * 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE185601T1 (de) 1990-07-10 1999-10-15 Cambridge Antibody Tech Verfahren zur herstellung von spezifischen bindungspaargliedern
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US7084260B1 (en) 1996-10-10 2006-08-01 Genpharm International, Inc. High affinity human antibodies and human antibodies against human antigens
JP2938569B2 (ja) 1990-08-29 1999-08-23 ジェンファーム インターナショナル,インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US5919452A (en) 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5656272A (en) 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
US5698195A (en) 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
ATE269401T1 (de) 1991-04-10 2004-07-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
WO1993006213A1 (en) 1991-09-23 1993-04-01 Medical Research Council Production of chimeric antibodies - a combinatorial approach
GB9122820D0 (en) * 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
DE69233782D1 (de) 1991-12-02 2010-05-20 Medical Res Council Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
EP0652950B1 (en) 1992-07-24 2007-12-19 Amgen Fremont Inc. Generation of xenogeneic antibodies
US5652138A (en) 1992-09-30 1997-07-29 The Scripps Research Institute Human neutralizing monoclonal antibodies to human immunodeficiency virus
ES2159529T5 (es) 1993-03-05 2011-03-09 Bayer Corporation Anticuerpos monoclonales humanos anti-tnf alfa.
CA2161351C (en) 1993-04-26 2010-12-21 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5654168A (en) 1994-07-01 1997-08-05 Basf Aktiengesellschaft Tetracycline-inducible transcriptional activator and tetracycline-regulated transcription units
CA2125763C (en) * 1993-07-02 2007-08-28 Maurice Kent Gately P40 homodimer of interleukin-12
EP0638644A1 (en) 1993-07-19 1995-02-15 F. Hoffmann-La Roche Ag Receptors of interleukin-12 and antibodies
EP0659766A1 (en) 1993-11-23 1995-06-28 Schering-Plough Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
ZA95960B (en) 1994-03-14 1995-10-10 Genetics Inst Use of interleukin-12 antagonists in the treatment of autoimmune diseases
US5910486A (en) * 1994-09-06 1999-06-08 Uab Research Foundation Methods for modulating protein function in cells using, intracellular antibody homologues
US5562138A (en) * 1994-10-13 1996-10-08 The Longaberger Company Bowing press
DE69637481T2 (de) 1995-04-27 2009-04-09 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US5853697A (en) * 1995-10-25 1998-12-29 The United States Of America, As Represented By The Department Of Health & Human Services Methods of treating established colitis using antibodies against IL-12
US6297395B1 (en) * 1995-11-10 2001-10-02 The Secretary Of State For Defence In Her Brittanic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland Calixarenes and their use for sequestration of metals
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US6258562B1 (en) 1996-02-09 2001-07-10 Basf Aktiengesellschaft Human antibodies that bind human TNFα
WO1998016248A1 (en) 1996-10-11 1998-04-23 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methods for enhancing oral tolerance and treating autoimmune disease using inhibitors of interleukin-12
PT936923E (pt) 1996-11-15 2004-04-30 Kennedy Inst Of Rheumatology Supressao de tnfalfa e il-12 em terapia
CA2273194C (en) 1996-12-03 2011-02-01 Abgenix, Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
EP0998300A1 (en) 1997-03-18 2000-05-10 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
US6054487A (en) 1997-03-18 2000-04-25 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
US6183744B1 (en) 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
WO1999009055A2 (en) 1997-08-18 1999-02-25 Innogenetics N.V. Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders
ATE274920T1 (de) 1997-10-31 2004-09-15 Wyeth Corp Verwendung von anti-il-12 antikörpern bei transplantationsabstossungen
JP4481489B2 (ja) 1998-01-23 2010-06-16 エフ.ホフマン−ラ ロシュ アーゲー ヒトil−12に対する抗体
US20020161199A1 (en) * 1998-04-08 2002-10-31 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP0953639A1 (en) 1998-04-30 1999-11-03 Boehringer Ingelheim International GmbH FAPalpha-specific antibody with improved producibility
DE69927520T2 (de) * 1998-12-09 2006-06-22 Protein Design Labs, Inc., Fremont Verwendung von il-12 antikörpern zur behandlung von psoriasis
US6914128B1 (en) * 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US7883704B2 (en) * 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
DK2168984T3 (da) * 1999-03-25 2012-12-10 Abbott Gmbh & Co Kg Humane antistoffer, som binder humant IL-12, og fremgangsmåder til pro-duktion heraf
PL202058B1 (pl) * 1999-08-09 2009-05-29 Merck Patent Gmbh Wielofunkcyjne białko fuzyjne cytokin i przeciwciała
US6902734B2 (en) * 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
AU2002256971B2 (en) 2000-12-28 2008-04-03 Altus Pharmaceuticals Inc. Crystals of whole antibodies and fragments thereof and methods for making and using them
WO2002097048A2 (en) 2001-05-30 2002-12-05 Centocor, Inc. ANTI-p40 IMMUNOGLOBULIN DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES
WO2002098445A1 (fr) * 2001-05-30 2002-12-12 Chugai Seiyaku Kabushiki Kaisha Preparation de proteines
JP2005529152A (ja) * 2002-05-17 2005-09-29 プロテイン デザイン ラブス インコーポレイティド 抗インターフェロンγ抗体を用いたクローン病又は乾癬の治療
JP2006502116A (ja) * 2002-07-12 2006-01-19 メダレックス, インク. タンパク質の酸化分解を防ぐ方法及び組成物
US20090280065A1 (en) 2006-04-10 2009-11-12 Willian Mary K Uses and Compositions for Treatment of Psoriasis
US7608260B2 (en) * 2003-01-06 2009-10-27 Medimmune, Llc Stabilized immunoglobulins
WO2004091510A2 (en) 2003-04-11 2004-10-28 Medimmune, Inc. Recombinant il-9 antibodies and uses thereof
CN101052726A (zh) 2003-05-09 2007-10-10 森托科尔公司 IL-23p40特异性免疫球蛋白衍生蛋白、组合物、方法和用途
JP2007503839A (ja) * 2003-09-04 2007-03-01 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ 新規UBP8rpポリペプチドおよび乾癬の治療におけるその使用
HUE026793T2 (en) * 2003-10-01 2016-07-28 Kyowa Hakko Kirin Co Ltd A method for stabilizing an antibody and a stabilized solution-type antibody preparation
EP1694317A4 (en) * 2003-12-19 2010-05-12 Protemix Corp Ltd COPPER ANTAGONIST COMPOUNDS
ES2967485T3 (es) 2003-12-23 2024-04-30 Genentech Inc Nuevos anticuerpos anti-IL 13 y usos de los mismos
EP1713502A1 (de) * 2004-02-12 2006-10-25 MERCK PATENT GmbH Hochkonzentrierte, flüssige formulierungen von anti-egfr-antikörpern
RU2292215C2 (ru) * 2004-05-21 2007-01-27 Дмитрий Васильевич Николенко Комплекс для лечения псориаза и способ лечения
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
US8008447B2 (en) 2004-07-23 2011-08-30 Genentech, Inc. Crystallization of antibody or fragment thereof
CN101120087A (zh) 2004-12-21 2008-02-06 森托科尔公司 抗-il-12抗体、表位、组合物、方法和用途
MX2007014440A (es) * 2005-05-16 2008-02-11 Abbott Biotech Ltd Uso de inhibidor de tnf para tratamiento de poliartritis erosiva.
EP1896073B1 (en) * 2005-06-30 2013-03-06 Janssen Biotech, Inc. Anti-il-23 antibodies, compositions, methods and uses
AU2007212147A1 (en) * 2006-02-03 2007-08-16 Medimmune, Llc Protein formulations
EP2639318B1 (en) 2006-09-11 2015-04-08 Celera Corporation Genetic polymorphisms associated with Psoriasis, methods of detection and uses thereof
SG175622A1 (en) 2006-10-13 2011-11-28 Centocor Ortho Biotech Inc Enhancement of hybridoma fusion efficiencies through cell synchronization
SG177982A1 (en) * 2007-01-16 2012-02-28 Abbott Lab Methods for treating psoriasis
AU2008233173B2 (en) * 2007-03-29 2013-09-19 Abbvie Inc. Crystalline anti-human IL-12 antibodies
BRPI0908715A2 (pt) 2008-03-18 2016-05-03 Abbott Lab métodos para tratamento da psoríase
US20120225080A1 (en) 2008-03-18 2012-09-06 Abbott Laboratories Human antibodies that bind the p40 subunit of human il-12/il-23 and uses therefor
BRPI0921320A2 (pt) * 2008-11-28 2018-05-22 Abbott Laboratories composições de anticorpo estáveis e métodos para estabilizar os mesmos
TW201127400A (en) * 2009-09-14 2011-08-16 Abbott Lab Methods for treating psoriasis
BR112013008528A2 (pt) 2010-10-06 2019-09-24 Abbvie Inc métodos para tratar psoríase
TW201242976A (en) 2011-01-07 2012-11-01 Abbott Lab Anti-IL-12/IL-23 antibodies and uses thereof

Also Published As

Publication number Publication date
RU2497545C2 (ru) 2013-11-10
NZ587765A (en) 2013-02-22
WO2009117289A3 (en) 2010-04-22
HK1203516A1 (en) 2015-10-30
CA2717569A1 (en) 2009-09-24
EP2274333A4 (en) 2011-06-15
RU2013132928A (ru) 2015-01-27
JP2011515404A (ja) 2011-05-19
EP2810954A3 (en) 2015-03-18
US8178092B2 (en) 2012-05-15
RU2010142309A (ru) 2012-04-27
WO2009117289A2 (en) 2009-09-24
EP2810954A2 (en) 2014-12-10
EP2274333A2 (en) 2011-01-19
US20120219562A1 (en) 2012-08-30
IL208069A0 (en) 2010-12-30
CN102037011A (zh) 2011-04-27
TWI461210B (zh) 2014-11-21
MX2010010265A (es) 2010-09-30
SG188909A1 (en) 2013-04-30
TW200948379A (en) 2009-12-01
TW201513883A (zh) 2015-04-16
US8945545B2 (en) 2015-02-03
NZ602511A (en) 2014-03-28
KR20100126515A (ko) 2010-12-01
AU2009225797A1 (en) 2009-09-24
US20100028363A1 (en) 2010-02-04

Similar Documents

Publication Publication Date Title
BRPI0908715A2 (pt) métodos para tratamento da psoríase
BRPI0910259A2 (pt) métodos de tratamento de inflamação
BRPI0911077A2 (pt) método para tratamento de biomassa
PT2349132T (pt) Aparelho para tratamento da drge
BRPI0910854A2 (pt) métodos de tratamento
BRPI0922871A2 (pt) metodos para o tratamento da esclerose múltipla usando pirazinoindóis tetracíclicos
BR112013007678A2 (pt) método para tratamento de doenças alérgicas
DK2361116T3 (da) Bestrålingsindretning
BRPI0917575A2 (pt) métodos de tratamento de talassemia
BR112012011730A2 (pt) tratamentos para distúrbios gastrointestinais
BRPI1013878A2 (pt) método para tratar distúrbios metabólicos, e, composto
DK2330887T3 (da) Behandlingsindretning
PT2340042E (pt) Métodos e composições para o tratamento de cancro
BRPI0914614A2 (pt) 2-arilaminoquinazolinas para tratar doenças proliferativas
BRPI0919127A2 (pt) métodos para tratamento de água
BRPI0813670A2 (pt) Compostos para tratamento
BRPI0909164A2 (pt) método e composições para o tratamento de câncer
BRPI0922884A2 (pt) compostos para tratamento de câncer
BRPI0909016A2 (pt) anticorpos úteis para o tratamento do câncer
BRPI0906606A2 (pt) Tratamento terapêutico para condições do pulmão.
HUE033690T2 (hu) Terápiás szer hangulatzavarokra
BRPI0822264A2 (pt) Dapsona para tratar rosácea
BRPI0922367A2 (pt) enzastaurin para o tratamento de câncer
BRPI1007543A2 (pt) tratamento de psoríase
BRPI0920728A2 (pt) Composição estabilizada para tratamento de psoríase

Legal Events

Date Code Title Description
B15I Others concerning applications: loss of priority

Free format text: PERDA DA PRIORIDADE US 61/207,904 DE 18/02/2009 REIVINDICADA NO PCT/US2009/036765, CONFORME AS DISPOSICOES PREVISTAS NA LEI 9.279 DE 14/05/1996 (LPI) ART. 16 7O, ITEM 28 DO ATO NORMATIVO 128/97 E NO ART. 29 DA RESOLUCAO INPI-PR 77/2013. ESTA PERDA SE DEU PELO FATO DE O DEPOSITANTE CONSTANTE DA PETICAO DE REQUERIMENTO DO PEDIDO PCT ("ABBOTT LABORATORIES") SER DISTINTO DAQUELE QUE DEPOSITOU A PRIORIDADE REIVINDICADA E NAO APRESENTOU DOCUMENTO COMPROBATORIO DE CESSAO, CONFORME AS DISPOSICOES PREVISTAS NA LEI 9.279 DE 14/05/1996 (LPI) ART. 16 6O, ITEM 27 DO ATO NORMATIVO 128/97 E NO ART. 28 DA RESOLUCAO INPI-PR 77/2013.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B25A Requested transfer of rights approved

Owner name: ABBVIE INC. (US)

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]